The Cardiovascular Reduction Early Anemia Treatment Epoetin β study showed that with mild-to-moderate anemia in p-CKDs, the normalization of Hb levels in the range of 13.0–15.0 g/dl did not reduce cardiovascular events compared with the effects of achieving a lower target range (10.5–11.5 g/dl) [19]. The gene discussed is GSTM1; the disease is anemia (phenotype).